Structure-guided development of purine amide, hydroxamate, and amidoxime for the inhibition of non-small cell lung cancer

An 8-oxopurine-6-carboxamide compound (1a) was previously identified as an inhibitor of non-small cell lung cancer (NSCLC). In this study, more than 30 purine-6-carboxamide derivatives with variations at the C2, N7, C8, and N9 positions were synthesized to investigate the structure−activity relation...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of medicinal chemistry 2019-11, Vol.181, p.111551-111551, Article 111551
Hauptverfasser:	Huang, Meng-Ruo, Hsu, Yuan-Ling, Lin, Tzu-Chen, Cheng, Ting-Jen, Li, Ling-Wei, Tseng, Yu-Wei, Chou, Yu-shu, Liu, Jyung-Hurng, Pan, Szu-Hua, Fang, Jim-Min, Wong, Chi-Huey
Format:	Artikel
Sprache:	eng
Schlagworte:	Amides - chemistry Amides - pharmacology Amidoxime Animals Antineoplastic Agents - chemical synthesis Antineoplastic Agents - chemistry Antineoplastic Agents - pharmacology Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - pathology Cell Line, Tumor Cell Proliferation - drug effects Dose-Response Relationship, Drug Drug Screening Assays, Antitumor Humans Hydroxamate Hydroxamic Acids - chemistry Hydroxamic Acids - pharmacology Lung cancer Lung Neoplasms - drug therapy Lung Neoplasms - pathology Mice Mice, Nude Microtubule Molecular Structure Neoplasms, Experimental - drug therapy Neoplasms, Experimental - pathology Oximes - chemistry Oximes - pharmacology Purine amide Purines - chemistry Purines - pharmacology Structure-Activity Relationship
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!